Therapy - immunomodulation - Part IThursday, September 29, 2005, 15:30 - 17:00
Clinical results of 3 year experience of Copaxone® in relapsing-remitting multiple sclerosis patients from a Moscow MS CentreA. Boiko, M. Davidovskaya, T. Deomina, N. Kchachanova, N. Lashch, N. Popova, N. Sinbuchova, E. Gusev (Moscow, RUS)
The aim of the study was to evaluate the effect of Copaxone® (Cop) treatment on relapse rate and disability progression in 104 patients with clinically definite relapsing remitting MS (RRMS) followed up in a 36-month open label study in Moscow MS Center. The mean age of patients at start was 37.5 (0.9) years, mean MS duration – 8.1 (0.6) years, mean EDSS score - 2.54 (0.10). The patients passed through neurological examination every 3 months.
Prior to the start of the DMT they have 1.45 (0.07) relapses per patient per year (149 on the whole), 2.69 (0.13) per patient during previous 2 years (277 on the whole). During these 3 years 42 patients (40.4%) were relapse free, 83 of them (79.8%) do not have EDSS progression. The relapse rate significantly decreased during the first year of treatment – 29 relapses on the whole (p<0,001), mean 0.28 (0.05), and remained stable low during the second year – 27 relapses, mean 0.26 (0.05) and the third year – 28 relapses, mean 0.27 (0.07). Thus in 3 years these 104 patients had only 84 relapses, which is near 2 times lower, then during one year prior to DMT.
During the first year increase in EDSS score was seen in 6 patients (5.8%), the second year – 7 patients (6.7%), the third year – 12 patients (11.5%). Mean EDSS score moved from 2.54 (0.10) at the start to 2.61 (0.13) 36 month later. In 9 patients (8.7%) disease transformed to secondary progressive MS (SPMS) with relapses and Cop treatment was stopped. Local side reactions were seem in 24 patients (26%), systemic reactions - in 9 cases.
Thus, in this group of patients Cop (used in every-day neurological practice) during the whole 3-year period showed stable positive influence on RRMS course – significant decrease of relapse rate, no EDSS progression in up to 80% of patients and good tolerability.